Lv2
106 积分 2025-07-16 加入
Integrative proteomic and phosphoproteomic profiling of invasive micropapillary breast carcinoma
1个月前
已完结
Integrative proteomic and phosphoproteomic profiling of invasive micropapillary breast carcinoma
1个月前
已完结
Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China
6个月前
已完结
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
6个月前
已完结
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
6个月前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
6个月前
已完结
Trastuzumab deruxtecan (T‐Dxd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY)
6个月前
已关闭
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
6个月前
已完结
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
6个月前
已完结
HER2-Low Breast Cancers
6个月前
已完结
Tumor Glycolytic Profiling Through 18F-FDG PET/CT Predicts Immune Checkpoint Inhibitor Efficacy in Advanced NSCLC
皖公网安备34019202002308
